Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
Category: Company News
IPI || Why the right approach to data management will enable the potential of small-molecule RNA sodifiers as drug targets to be fulfilled
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Biocompare || Peptidomics: Methods in the search for molecular disease signatures
Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.
Bio-IT World || Lessons From the Recent HCA 2022 General Meeting: Applying Single-Cell Data to Clinical Decision Making
The recent Human Cell Atlas (HCA) 2022 General Meeting, hosted in Vienna, Austria, provided a great opportunity for me to catch up on progress towards the HCA’s goal of mapping every cell type in the human body. I also got the chance to hear presentations that either highlighted new insights gleaned from HCA data or described the outcomes from ongoing collaborations between research groups.
Clinical Laboratory || Paradigm4 introduces Precision Cell Atlas for REVEAL: SingleCell app
Paradigm4 has introduced the ‘Precision Cell Atlas’ as an integral component of its REVEAL: SingleCell app. The Precision Cell Atlas enables scientists to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives and explicitly saving them for collaboration, reuse, and regulatory filings
Pharma’s Almanac || What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
insideBIGDATA || Big Data in Life Sciences – Why ‘doing things the old way’ is the Biggest Barrier to Progress
Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.
Bio-IT World || The Role Of Bioinformatics In Bringing Biobanks To The Forefront Of Scientific Breakthroughs
Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support better understanding of disease etiology
Biospace || Paradigm4 Joins the Tetra Partner Network to Leverage Tetra Data into High-performing Analytical Computing Applications for Pharmaceutical Customers
TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.
International Pharmaceutical Technology | 1 Trillion Cells, 50 Million Individuals
Calculating the true value of scientific data storage platforms is the goal of every developer. With millions of cells to analyze, digital solutions are the key